Limits...
Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib.

Houriet C, Klass ND, Beltraminelli H, Borradori L, Oberholzer PA - Case Rep Dermatol (2014)

Bottom Line: Their use results in various cutaneous side effects, such as the development of keratoacanthomas and squamous cell carcinomas.The cystic lesions were observed only in the localized area where a large exophytic melanoma tumor mass had been previously irradiated.Localized epidermal cysts may constitute an unusual radiation recall reaction in patients treated with BRAF inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Inselspital, University of Berne, Berne, Switzerland.

ABSTRACT
BRAF inhibitors are broadly used for metastatic melanoma with BRAF mutations. Their use results in various cutaneous side effects, such as the development of keratoacanthomas and squamous cell carcinomas. We report a patient with metastatic melanoma treated with vemurafenib who developed dozens of histologically confirmed epidermal cysts within 2 months after initiation of vemurafenib administration. The cystic lesions were observed only in the localized area where a large exophytic melanoma tumor mass had been previously irradiated. Localized epidermal cysts may constitute an unusual radiation recall reaction in patients treated with BRAF inhibitors.

No MeSH data available.


Related in: MedlinePlus

Development of several epidermal cysts in the head and neck area where a large exophytic melanoma tumor mass had been previously irradiated.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4209266&req=5

Figure 1: Development of several epidermal cysts in the head and neck area where a large exophytic melanoma tumor mass had been previously irradiated.

Mentions: Because of the advanced stage of the tumor palliative, neoadjuvant, hypofractionated radiotherapy was started. The exophytic tumor in the neck was given a total radiation dose of 30 Gy with 6 × 5 Gy per daily fraction administered 5 days per week. Based on the detection of a BRAF mutation V600E in exon 15, the patient was given vemurafenib (Zelboraf®) 960 mg twice daily 3 days after completion of the radiotherapy. At the follow-up visit 3 months after radiotherapy, the patient was found to have multiple epidermal cysts in the previous irradiation field, i.e. the left temple, ear and auditory canal and posterior neck region (fig. 1). Light microscopy studies confirmed the diagnosis (fig. 2). At the 1-year follow-up visit the patient's situation was stable and the number of epidermal cysts unchanged.


Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib.

Houriet C, Klass ND, Beltraminelli H, Borradori L, Oberholzer PA - Case Rep Dermatol (2014)

Development of several epidermal cysts in the head and neck area where a large exophytic melanoma tumor mass had been previously irradiated.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4209266&req=5

Figure 1: Development of several epidermal cysts in the head and neck area where a large exophytic melanoma tumor mass had been previously irradiated.
Mentions: Because of the advanced stage of the tumor palliative, neoadjuvant, hypofractionated radiotherapy was started. The exophytic tumor in the neck was given a total radiation dose of 30 Gy with 6 × 5 Gy per daily fraction administered 5 days per week. Based on the detection of a BRAF mutation V600E in exon 15, the patient was given vemurafenib (Zelboraf®) 960 mg twice daily 3 days after completion of the radiotherapy. At the follow-up visit 3 months after radiotherapy, the patient was found to have multiple epidermal cysts in the previous irradiation field, i.e. the left temple, ear and auditory canal and posterior neck region (fig. 1). Light microscopy studies confirmed the diagnosis (fig. 2). At the 1-year follow-up visit the patient's situation was stable and the number of epidermal cysts unchanged.

Bottom Line: Their use results in various cutaneous side effects, such as the development of keratoacanthomas and squamous cell carcinomas.The cystic lesions were observed only in the localized area where a large exophytic melanoma tumor mass had been previously irradiated.Localized epidermal cysts may constitute an unusual radiation recall reaction in patients treated with BRAF inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Inselspital, University of Berne, Berne, Switzerland.

ABSTRACT
BRAF inhibitors are broadly used for metastatic melanoma with BRAF mutations. Their use results in various cutaneous side effects, such as the development of keratoacanthomas and squamous cell carcinomas. We report a patient with metastatic melanoma treated with vemurafenib who developed dozens of histologically confirmed epidermal cysts within 2 months after initiation of vemurafenib administration. The cystic lesions were observed only in the localized area where a large exophytic melanoma tumor mass had been previously irradiated. Localized epidermal cysts may constitute an unusual radiation recall reaction in patients treated with BRAF inhibitors.

No MeSH data available.


Related in: MedlinePlus